Company ProfilePremium

Add-Shop E-Retail Limited

Company Profile Analysis

Ticker: 541865.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Add-Shop E-Retail Limited - Company showcase

Year Founded & Workforce

2013

Add-Shop E-Retail Limited logo

Add-Shop E-Retail Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Add-Shop E-Retail Limited Overview

Add-Shop E-Retail Limited is a Rajkot-based micro-cap that markets and distributes Ayurvedic healthcare products, nutraceuticals and food supplements, organic agricultural inputs (soil conditioners and organic fertilisers), animal feed supplements, herbal personal care, household and women's hygiene products under the "Add-Shop" brand. Distribution runs through a franchise and direct-selling network concentrated in rural and semi-urban India, with particular depth in Karnataka, Andhra Pradesh, Telangana and Gujarat. The company is closely intertwined with promoter-group entities: Dada Organics Ltd (founded 2004 by the promoters), Dadaji Lifescience Pvt Ltd and Scarnose International Ltd. Shareholders have approved related-party transactions with these entities of up to INR 250 crore per year, which exceeds the company's entire revenue. After explosive growth from FY2019 to FY2023, culminating in a INR 48.9 crore rights issue in 2022, margins collapsed from about 15% to about 2%. Receivable days stretched to 264, promoter holding fell to 27%, and the stock trades at roughly 0.14x book value.


Company's own description

The company's filings describe it in several overlapping ways that have shifted over time:

  • FY2024-25 annual report (as summarised by Screener, citing p.48): The company is engaged in trading and distribution of organic fertilisers, Ayurvedic medicines and herbal cosmetic products.

Strategic update to BSE, 19 Dec 2023: The company presents itself as a prominent direct selling company based in Rajkot. Its range covers supplements, Ayurvedic medicine, nutraceuticals, food supplements, herbal cosmetics, personal care, household items and women's hygiene products. It stresses nutraceuticals aimed at post-COVID needs and urban lifestyles, including protein products.

MCA/IIFL company summary: The company markets and distributes Ayurvedic, food supplement, agricultural, animal feed supplement and personal care products. It distributes organic products to farmers for agricultural use and organic cattle-feed products for livestock.

Press releases (Oct 2022, Apr 2022): The company calls itself one of the country's first companies to promote organic farming and produce organic farm goods. It claims the promoter lobbied government on organic farming about 20 years earlier, which predates the company and refers to the promoter's personal work.

  • Data-aggregator description (Upstox, derived from S&P/Refinitiv): The company manufactures through two fully automated manufacturing units.

Business model

ElementCharacterisation
Core activityBranded distribution (largely asset-light) of FMCG-like health, agri-input and personal care SKUs
ChannelFranchise outlets ("Add-Shop" franchises, often branded locally as organic/Ayurveda/"savayava" shops), C&F (carrying & forwarding) agents, a direct-selling member network and an e-commerce ordering platform for members
Customer types(1) Franchisees and distributors (B2B); (2) farmers buying organic agri-inputs and cattle-feed supplements; (3) retail consumers buying Ayurveda, nutraceutical and personal care products; (4) direct-selling "members/associates"
End-marketsIndian rural agri-inputs (organic/bio-fertiliser, soil conditioners); animal nutrition supplements; Ayurvedic OTC/wellness; nutraceuticals; herbal personal care; household consumables; Khadi apparel (per aggregator descriptions)
Revenue modelAlmost entirely product sales (trading/distribution margin). No disclosed subscription, licensing or service revenue. Franchise fees, if any, are not separately disclosed
Value-chain positionMid-stream brand-owner/distributor. Upstream sourcing is partly from promoter-group manufacturers (Dada Organics, Dadaji Lifescience); downstream sales go through franchisees and members rather than organised retail
Geography100% domestic India (no export revenue disclosed despite 2022 press-release mentions of export ambitions)

Independent characterisation

Add-Shop is best understood as a promoter-led, network-marketing-style distributor of low-ticket rural consumables. Its economics depend on a few things: (a) recruitment and activation of franchisees and members; (b) credit extended to the channel; and (c) sourcing terms with related parties. The FY2021–FY2023 surge (revenue from INR 78 crore to about INR 197 crore, PAT about INR 19 crore per year) coincided with aggressive franchise additions, two bonus issues and a INR 48.9 crore rights issue. Since FY2024 the business shows the hallmarks of a channel that has been over-stuffed or under-collected:

  • Debtor days rose from 53 (FY2022) to 264 (FY2026).

  • The cash conversion cycle widened from 102 to 333 days.

  • Cumulative operating cash flow over FY2023–FY2025 was negative INR 74 crore.

  • Operating margins fell from about 15–16% to about 2%.

Revenue has stabilised at about INR 155 crore in FY2025 and FY2026 and grew 55% YoY in Q1 FY2027. However, profit per rupee of sales is now minimal. The governance structure (27% promoter holding, family directors, large related-party approvals, frequent auditor, CFO and CS turnover) is the central analytical issue.

Strategy

Stated strategy themes (from BSE business updates and press releases, 2021–2023)

No investor-day material or formal medium-term strategy document exists. The recurring themes in management communications are:

  1. Distribution-network leverage. Management repeatedly says it will leverage its robust distribution network across the country for Ayurvedic and agriculture products, expanding by state through franchises and C&F agents.

  2. Product-range expansion. It frames itself as continually developing new health-related products, such as the 7 Ayurveda launches (Dec 2021), the 14-product pipeline (Jan 2022), spices, tea and coffee (Jul 2022) and tulsi green tea (Feb 2023).

  3. E-commerce enablement. A member platform lets franchisees and partners order from anywhere, with doorstep delivery.

  4. Farmer-centric organic agriculture. "Poison-free farming" positioning, with farmer recognition programmes.

  5. Post-COVID nutraceuticals and urban lifestyle products. Protein and nutraceutical products for urban consumers (Dec 2023 strategic update).

  6. Capacity and export ambitions. The Q2 FY2023 press release mentions further strategic initiatives to add incremental capacity and to explore exports.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
Related-party sourcing/sales framework renewalAug–Sep 2026Board (27 Aug 2026) and AGM (19 Sep 2026) approved material RPTs with Dada Organics, Dadaji Lifescience and Scarnose International (aggregate cap reported as up to INR 250 crore)Approved
Debt reduction / working-capital releaseFY2026Borrowings cut from about INR 38 crore to about INR 25 crore; CFO turned positive at INR 8 croreAchieved FY2026
Governance/compliance appointmentsMay 2025; Aug 2026Secretarial auditor and internal auditor appointments; secretarial auditor change approvedOngoing
New franchise or product launches—None announced to BSE in the last 24 months in sources reviewed—
ESG / sustainability commitments—None disclosed—
Cost programmes with targets—None disclosed—

Medium-term targets / guidance

Management has not issued any quantitative guidance or medium-term financial targets.

Products & Services

The company does not publish a SKU-level catalogue in its exchange filings, and no pricing is disclosed. The catalogue below is compiled from BSE business updates, press releases and aggregator business descriptions. Launch years reflect the announcement date.

Ayurveda & nutraceuticals

Product / lineDescriptionTarget customerLaunch / latestSource
GAUPIYUSH CapsuleAyurvedic preventive health capsule positioned for all age groupsRetail consumers via franchise networkPromoted Jan 2022IssueWire release, 30 Jan 2022
Aloe Vera GelHerbal gel, part of a 7-product Ayurveda launchRetail consumersDec 2021 – Jan 2022BSE update 10 Jan 2022
Immunity-oriented Ayurveda range (7 products)Ayurveda-based products launched to expand range; names other than Aloe Vera Gel not disclosedRetailDec 2021BSE update 27 Dec 2021
Pipeline of 14 health & household productsUnder development as of Jan 2022; launch status not disclosedRetailAnnounced Jan 2022BSE update 10 Jan 2022
Nutraceuticals / specialised protein productsPost-COVID nutraceuticals aimed at urban lifestyles, including protein supplementsUrban consumersReferenced Dec 2023BSE strategic update 19 Dec 2023
Food supplementsGeneral food-supplement categoryRetailOngoingMCA/IIFL summary

Food & beverages

Product / lineDescriptionLaunch / latestSource
Instant Green Tea with Tulsi ExtractInstant herbal teaFeb 2023BSE update 6 Mar 2023
Spices, tea & coffee rangeAnnounced for national distribution under the Add-Shop brand, citing government food manufacturing licensingAnnounced Jul 2022BSE update 25 Jul 2022

Agriculture inputs

Product / lineDescriptionTarget customerSource
Organic fertilisers / soil conditionersCore agri line; the FY2025 annual report names organic fertilisers as a principal traded categoryFarmers (strong in Karnataka)Screener citing FY2025 AR; MarketScreener
Organic farming products"Poison-free farming" positioning linked to the promoter's missionFarmersPress releases 2022

Animal nutrition

Product / lineDescriptionTarget customerSource
Organic cattle-feed / animal feed supplementsSupplements for livestockDairy farmersMCA/IIFL summary; press release Oct 2022

Personal care, household & other

Product / lineDescriptionSource
Herbal cosmetics / personal careHerbal cosmetic and personal care rangeFY2025 AR (via Screener); Dec 2023 update
Household items / home careEveryday-use productsDec 2023 update; MarketScreener
Women's hygiene productsWomen's hygiene range (promoter-group Dada Organics also lists sanitary pads)Dec 2023 update; IndiaMART
Khadi clothingDistribution of Khadi apparelInvesting.com / MarketScreener descriptions
Books and othersListed in aggregator descriptionInvesting.com

Platforms and services

PlatformDescriptionSource
E-commerce member platformMember/franchise ordering platform with doorstep delivery to franchisees; the basis for the 2020 renameBSE updates Jan 2022, Aug 2022
Franchise modelAdd-Shop branded franchise outlets plus C&F agents; franchise fees not disclosedBSE updates 2021–2023

Pricing model: Not publicly disclosed. Products are sold at MRP-based retail prices through franchisees, with trade margins to the channel.

Financial Narrative

Basis: standalone, INR crore. Primary source is Screener.in (C-MOTS data derived from audited annual results), cross-checked with Business Standard/Capital Market summaries and company press releases. Some Screener annual figures are rounded to whole crore; precise figures are used where a primary or press source provides them.

Income statement

Note on gross profit: Gross profit (revenue less cost of goods) is not separately available in the sources accessed. Screener's "Expenses" line combines COGS and operating costs. Gross profit is therefore not publicly disclosed in the sources reviewed.

Quarterly trajectory (13 quarters)

Source: Screener quarterly results; Business Standard for Q1FY25 and Q4FY25 cross-checks.

Data-quality flag: One aggregator (Univest blog, May 2026) reported Q4 FY2026 revenue of "Rs 18 crore" and PAT of "Rs 1.5 crore". This conflicts with filed-results-derived data (INR 56.99 crore revenue; INR 0.36 crore PAT) and appears to be an automated error.

Balance sheet

Items not publicly disclosed in the sources reviewed:

Cash and cash equivalents: Screener's net cash flow lines (+1, -1, +1, -1, 0) imply cash balances of no more than about INR 1–2 crore.

  • Given the working-capital-heavy profile and the 2022 AGM approval to give security for loans of up to INR 50 crore, borrowings are likely predominantly short-term working-capital facilities.

Goodwill and intangibles: None disclosed; assumed nil (no acquisitions).

Derived metrics:

Net debt: approximately equal to gross borrowings given minimal cash. Approx. INR 25 crore at FY2026, down from about INR 38 crore at FY2025.

  • Working capital (other assets less other liabilities and borrowings): about INR 33 (FY2022), 100 (FY2023), 104 (FY2024), 107 (FY2025) and 108 crore (FY2026). Nearly all equity, including the INR 48.9 crore rights proceeds, is tied up in working capital.

Interim data point: Total assets at 30 Sep 2025 were INR 129.57 crore, versus INR 155.46 crore at 31 Mar 2025 (ScanX summary of H1 FY2026 results).

Cash flow

Commentary on cash flow: The FY2023 financing inflow of INR 45 crore is the rights issue, and the same year's operating outflow of INR 45 crore shows the proceeds were consumed by working capital (receivables and inventory).

Large investing flows in FY2024 (+INR 9 crore), FY2025 (-INR 15 crore) and FY2026 (+INR 18 crore) are unusual for a company with negligible capex. They most likely represent loans and advances given and recovered, or deposits, possibly with related parties. The nature of these flows is not publicly disclosed in the sources reviewed and should be verified in the annual report cash flow notes.

The FY2026 reversal (positive CFO of INR 8 crore and investing inflow of INR 18 crore) funded about INR 27 crore of financing outflow, chiefly debt reduction from INR 38 crore to INR 25 crore.

Ratios

Ratio notes:

Current ratio: Not computable precisely without the current/non-current split. Using other assets ÷ (other liabilities + borrowings) as a proxy gives about 4.0x (FY2022), 3.3x (FY2023), 7.5x (FY2024), 3.5x (FY2025) and 3.8x (FY2026). The high ratio reflects receivable build-up rather than liquidity.

ROIC proxy: EBIT ÷ (equity + debt), approximate.

Interest coverage: FY2022–FY2023 values use rounded interest of INR 1 crore and are approximate.

Commentary on trends, inflections and drivers

Phase 1 — Hyper-growth (FY2019–FY2023). Revenue rose roughly ninefold from INR 22 crore (FY2019) to about INR 197 crore (FY2023). Operating margins expanded to 15–16%. Management attributed the growth to franchise additions across southern and eastern states, the e-commerce member platform and new Ayurveda/immunity products during COVID. Debtor days, however, jumped from 53 to 167 in FY2023 alone. Profit growth was recognised in the income statement but was not converting to cash (CFO of -INR 45 crore in FY2023).

Phase 2 — Margin collapse (FY2024). Revenue held at INR 203 crore but OPM fell to 3.7%. Q4 FY2024 recorded a INR 9.6 crore operating loss (OPM -16.4%) and a INR 6.99 crore net loss, with an effective tax rate of 48% for the year. The Q4 loss is consistent with a year-end write-down, provisioning or margin give-back to the channel. No explanation was available in the sources accessed. This inflection coincided with two statutory auditor resignations (Aug 2023, Feb 2024) and wholesale board changes.

Phase 3 — Contraction and stagnation (FY2025–FY2026). FY2025 revenue fell 23.6% to INR 155 crore. Debt rose to INR 38 crore to fund a further INR 10 crore operating cash outflow, and debtor days hit 229. In FY2026 revenue was flat, OPM halved to 2.1%, and PAT fell 68% to INR 1.05 crore. Cash flow improved: CFO was +INR 8 crore and debt was cut by about INR 13 crore, possibly through recovery of advances (investing inflow of INR 18 crore).

Phase 4 — Q1 FY2027 volume rebound without margin. Revenue of INR 45.64 crore (+55% YoY) is the second-highest quarter since Q4 FY2024. OPM stayed at 1.9% and PAT at INR 0.27 crore. TTM revenue is about INR 171 crore and TTM PAT about INR 1.12 crore. The business is regaining volume but has not restored pricing power or channel margins.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Related Entity Details

Related entityRelationshipBusinessListed?

Dada Organics Ltd (formerly Dada Organics Pvt Ltd)

Founded 2004 by Dineshbhai and Jayshree Pandya; Dev Pandya a director since 29 Aug 2017

Manufactures and markets animal feed, Ayurveda, agricultural and herbal cosmetic/personal care products (incl. sanitary pads per IndiaMART listing)

—

Dadaji Lifescience Pvt Ltd

Dev Pandya a director

Not publicly disclosed; RPT counterparty since at least FY2023

No (private)

Scarnose International Ltd

Dev Pandya and Jigar Pandya appointed directors 26 Mar 2024 (Dev exited 29 May 2024)

Cotton bales/yarn trading, readymade garments

Yes, BSE 543537

Dadaji Home Mart

Promoters' venture launched c. Jan 2022

Retail of Ayurvedic/household products

—

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue (INR Cr)

203.06155.13154.65

Operating profit before D&A (INR Cr)

7.576.283.29

Pre-tax income (INR Cr)

6.064.521.51

Operating margin (%)

3.734.052.13

YoY revenue growth (%)

1.6-23.6-0.3

Contribution to total revenue (%)

100100100

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

159.65197203.06155.13154.65

Total expenses excl. D&A and interest (INR Cr)

131168195.49148.85151.36

Operating profit / EBITDA (INR Cr)

25297.576.283.29

Other income (INR Cr)

00000

Interest expense (INR Cr)

111.031.211.20

Depreciation (INR Cr)

0.40.60.500.550.58

Pre-tax income (INR Cr)

23276.064.521.51

Tax rate (%)

1930482730

Net income (INR Cr)

19.0919.23.163.321.05

EPS basic (INR)

4.966.771.121.170.37

EPS diluted (INR)

4.966.771.121.170.37

Dividend per share (INR)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA / operating margin (%)

16153.734.052.13

Pre-tax margin (%)

14.413.73.02.91.0

Net margin (%)

12.09.71.62.10.7

Revenue YoY growth (%)

103.223.43.1-23.6-0.3

Net income YoY growth (%)

146.60.6-83.55.1-68.4

CAGR by Period

PeriodCAGR

FY2021 (INR 78 crore) → FY2026 (INR 154.65 crore), 5-year

approx. 14.7% (Screener 5-yr: 15%)

FY2023 → FY2026, 3-year

approx. -7.6% (Screener: -8%)

FY2022 → FY2026, 4-year

approx. -0.8%

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (INR Cr)

47.3240.3756.9958.3840.3631.2033.8349.7329.4133.4034.8556.9945.64

Operating profit (INR Cr)

7.413.514.42-9.602.091.621.670.900.770.750.800.970.86

OPM (%)

15.668.697.76-16.445.185.194.941.812.622.252.301.701.88

Net profit (INR Cr)

5.272.352.52-6.991.150.880.920.360.210.230.260.360.27

EPS (INR)

1.860.830.89-2.470.410.310.320.130.070.080.090.130.10

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

51151126155152

Fixed assets, net (INR Cr)

76656

Other assets: receivables, inventory, cash, loans (INR Cr)

44144120150146

Total borrowings (INR Cr)

31133825

Other liabilities incl. payables (INR Cr)

8433513

Equity share capital (INR Cr)

1928282828

Reserves (INR Cr)

2079828586

Shareholders' equity (INR Cr)

39107110113114

Book value per share (INR)

20.337.838.939.940.2

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

9-45-19-108

Investing cash flow (INR Cr)

-3-19-1518

Financing cash flow (INR Cr)

-5451124-27

Net cash flow (INR Cr)

1-11-10

Free cash flow (INR Cr)

6-45-19-107

Capex, approx. (INR Cr)

30001

CFO / operating profit (%)

45-134-209-131242

Dividends paid (INR Cr)

00000

Buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

64.726.32.93.00.9

ROA on average assets (%)

39.819.02.32.40.7

ROCE (%), Screener

6938642

ROIC, pre-tax proxy (%)

5826642

Debt / equity (x)

0.080.010.120.340.22

Net debt / EBITDA (x)

0.10.01.76.07.6

Interest coverage, EBIT / interest (x)

24.628.46.94.72.3

Asset turnover (x)

3.251.951.461.091.01

Debtor days

53167155229264

Inventory days

596854100102

Payable days

10864833

Cash conversion cycle (days)

102148206320333

Working capital days

81159176207284

Revenue by Region

RegionFY2024FY2025FY2026

India (INR Cr)

203.06155.13154.65

Outside India (INR Cr)

000

State Details

StateDisclosed expansion activityDate(s)

Karnataka

26 franchises + 4 C&F (Jul 2022); most of 25 franchises (Aug 2023); farmer award programmes in Bengaluru

2022–2023

Andhra Pradesh

21 franchises

May 2022

Telangana

14 franchises

May 2022

Tamil Nadu

10 franchises

Feb 2023

West Bengal

10 franchises

Feb 2023

Bihar

7 franchises

Feb 2023

Maharashtra, Uttar Pradesh

Franchises opened (part of 8 across 3 states)

Nov–Dec 2021

Gujarat

Home state (Rajkot HQ)

Ongoing

Valuation Snapshot

MetricValueSource

Latest close

INR 5.76 (8 Oct 2026)

MarketsMojo

52-week high / low

INR 10.00 / 5.26

Screener (Sep 2026)

All-time low (reported)

INR 6.30 on 24 Aug 2026, subsequently breached

MarketsMojo

1-year return

-42% (Screener); -40.9% (ScanX)

—

3-year price CAGR

-46% per year

Screener

5-year price CAGR

-38% per year (Screener); cumulative 5Y -91% (ScanX)

—

IPO price (2018)

INR 26; bonus-adjusted about INR 8.74 (after 3:4 and 7:10 bonuses)

Derived

Rights price (2022)

INR 54; current price about 89% lower

Derived

Beta

-0.77 (Simply Wall St)

—

Valuation Multiples

MultipleAdd-ShopBasis

P/E (TTM)

About 14.8x

TTM EPS INR 0.40 (Screener)

P/B

About 0.14x

Book value INR 40.2

EV/Sales

About 0.24x

EV ≈ INR 16.3 crore market cap + INR 25 crore debt − minimal cash ≈ INR 41 crore; TTM sales INR 171 crore

EV/EBITDA

About 12–13x

TTM EBITDA about INR 3.4 crore

Dividend yield

0%

No dividends ever paid

Operating Metrics (count) and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Shareholders (count)

22,77446,88940,11835,02231,376

Promoter holding (%)

58.0736.0327.2027.2027.20

Book value per share (INR)

20.337.838.939.940.2

EPS (INR)

4.966.771.121.170.37

Capital Markets

ItemDetail

Dividend history & policy

No dividend declared since listing (0% payout every year, FY2017–FY2026). Screener flags "reporting repeated profits, not paying out dividend." No formal dividend policy disclosed

Corporate actions

Bonus 3:4 (Jul 2020); bonus 7:10 (Jan 2022); rights at INR 54 (Aug–Sep 2022). equity capital has stayed at INR 28.31 crore since FY2023

Credit ratings (Moody's/S&P/Fitch)

None. No domestic rating (CRISIL/ICRA/CARE) identified in sources reviewed

Debt maturity profile

Not publicly disclosed. Borrowings of about INR 25 crore (FY2026) are presumed short-term working-capital lines

Analyst consensus

No coverage

Analyst Conclusions

Guidance and consensus

Management provides no guidance, and no analyst consensus exists. Run-rate indicators:

  • TTM revenue about INR 171 crore (+19% TTM).

  • TTM PAT about INR 1.12 crore (-53% TTM).

  • Q1 FY2027 revenue INR 45.64 crore at 1.9% OPM.

Annualising Q1 FY2027 implies FY2027 revenue of about INR 170–190 crore. Unless OPM recovers, PAT would remain in the INR 1–2 crore range. This is an analyst extrapolation, not guidance.

Bull case

  1. Asset backing with release potential. Book value of INR 40.2/share vs. a price of about INR 5.8. If receivables (264 days) normalise toward FY2022's 53 days, INR 40–50 crore of cash could be released, about three times the market cap. FY2026 already showed CFO of +INR 8 crore and debt cut by INR 13 crore.

  2. Volume re-acceleration. Q1 FY2027 revenue rose 55% YoY. Operating leverage on a largely fixed overhead base could restore mid-single-digit margins. Each 1 percentage point of OPM on about INR 180 crore of revenue adds about INR 1.8 crore of EBITDA, roughly doubling current earnings.

  3. Proven historic earnings power. The company earned INR 19 crore PAT in each of FY2022 and FY2023 on a similar asset base. Even a partial recovery would put the stock on a very low multiple.

Bear case

  1. Earnings quality and related parties. RPT caps of up to INR 250 crore with promoter entities exceed total revenue. Opaque investing flows (±INR 9–18 crore per year) and 264 debtor days leave outsiders unable to verify the economic substance of sales or receivables.

  2. Governance signals. Two auditor resignations within six months, three CFOs and three company secretaries since 2023, a promoter stake down to 27% and a combined Chair/MD role all point to elevated governance risk that typically keeps such stocks at deep discounts to book indefinitely.

  3. Structural margin erosion. OPM has fallen for four straight years (16% to 2.1%), and the Q1 FY2027 revenue rebound came at 1.9% OPM. This suggests volume is being bought through channel margins or credit, not earned through brand strength.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it mattersExpected timing
Q2 FY2027 resultsWhether 55% growth persists and whether OPM rises above 3%By mid-Nov 2026
H1 FY2027 balance sheet (Sep 2026)Receivable and inventory trend; borrowingsWith Q2 results
Half-yearly RPT disclosureActual transaction values with Dada Organics, Dadaji Lifescience, ScarnoseNov–Dec 2026 and May 2027
Appointment of a new Company SecretaryLODR compliance continuityOverdue since Apr 2026
FY2026 annual report notesAuditor opinion and any emphasis of matter; loans and advances to related parties; receivable ageing and expected credit loss provisioning; contingent liabilitiesAlready filed (27 Aug 2026); requires review
Promoter shareholding changes / pledgesAlignment signalQuarterly shareholding filings
Any resumption of business updates (franchise or product launches)Signal of commercial re-engagementAd hoc

Analyst verdict

Add-Shop E-Retail is a case study in how a fast-growing rural distribution story can turn into a capital trap. Between FY2021 and FY2023 the company quadrupled revenue to about INR 197 crore, reported roughly INR 19 crore of annual profit, issued two bonus rounds and raised INR 48.9 crore from public shareholders at INR 54 per share. Three years later the same business earns about INR 1 crore a year on more than INR 150 crore of sales. About INR 108 crore of shareholder capital sits in working capital, receivables take 264 days to collect, and the share price of about INR 5.8 is below even the bonus-adjusted 2018 IPO price.

The bull thesis is arithmetic: a price-to-book of 0.14x, a debt load of only 0.22x equity, a FY2026 cash-flow turnaround and a 55% revenue rebound in Q1 FY2027. If receivables are genuine and collectible, the equity is worth several times the market price.

That "if" is the entire investment question. Related-party transaction frameworks exceed annual revenue. Investing cash flows swing by up to INR 18 crore a year with no disclosed explanation. Two statutory auditors resigned within six months, and finance and compliance leadership has turned over repeatedly. The promoter, who owns only about 25%, controls the board through family directors and an executive chair. None of these is proof of impropriety, but together they explain why the market refuses to credit the book value.

Verdict: High-risk, low-visibility micro-cap. Priorities for that review are receivable ageing, expected-credit-loss provisioning, related-party balances and the auditor's report. A re-rating requires two to three consecutive quarters of positive operating cash flow, falling debtor days and a stable, independent finance and audit function. Until then the discount to book is better read as a risk premium than a margin of safety.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackground / prior rolesAgeLatest compensation

Dineshbhai (Dineshkumar) Bhanushankar Pandya (DIN 06647303)

Promoter, Chairman & Managing Director

Director since 20 Aug 2013; MD since 31 May 2018

Visually impaired first-generation social entrepreneur; about 20 years of work on "Poison Free Farming, Rich Farmer, Progressive Village"; co-founder of Dada Organics (2004); described as "leading industrialist of Gujarat"

48–51 (sources conflict)

—

Shraddha Dev Pandya

Executive Director (appointed Additional Executive Director 2023)

Since 2023

———

Maharshi Jigar Pandya

Executive Director (appointed Additional Executive Director 2023)

Since 2023

Promoter family member (inferred)

——

Jayshree (Jayshreeben) Dineshbhai Pandya

Non-Executive Director (earlier Executive Director)

Since 2017

Co-founder of Dada Organics; co-launched Dadaji Home Mart

About 52 (Investing.com)

Received director remuneration in H2 FY2023 per RPT disclosure; amount illegible in source

Rajen P. Vyas

Chief Financial Officer

Since 10 Jul 2024

———

“—” = not publicly disclosed.

Board of Directors — Maulik M. Chavda

NameRoleAppointedNotes

Maulik M. Chavda

Non-Executive Independent Director; committee member

28 May 2024

Appointed during the May 2024 reconstitution

Dhrumil Rameshbhai Gokani

Additional Non-Executive Independent Director

Nov 2023

—

Vivek Dadhania

Independent Director

—

Listed on MarketsMojo board list

Kinjal Khunt

Independent Director

—

Listed on MarketsMojo board list

Jitendra Pradipbhai Parmar

Independent Director

—

Listed on Investing.com (age 33)

Manish Shrichand Bachani

Independent Director

—

Listed on Investing.com (age 33)

Governance Overview

DimensionAssessment

Chair/CEO separation

Not separated: Dineshbhai Pandya is Chairman and MD

Family representation

4 of about 8 directors are from the promoter family

Independence

About 50% on paper; Simply Wall St notes an average board tenure of about 1.5 years, so the board is effectively newly constituted

Turnover

Very high: at least 6 independent director exits (2023–2024), 3 CFO changes (Aug 2023, Jul 2024), 3 CS changes (Sep 2023 appointment, Apr 2024 and Apr 2026 resignations), 2 statutory auditor resignations (Aug 2023, Feb 2024)

Board & Management Changes

DateChangeContext

8 Aug 2023

Statutory auditor resignation accepted

Firm name not captured in sources accessed

19 Aug 2023

Dev Dineshbhai Pandya resigns as Director & CFO

Later joined the Scarnose International board (Mar 2024)

19 Aug 2023

Jigar Dineshkumar Pandya and Deviben Dineshbhai Pandya resign as directors

Promoter family members exit the board

19–21 Aug 2023

Independent directors Yagnik Mundadiya and Rushabh Vora resign

—

1 Sep 2023

New Company Secretary appointed

Per FY2023 annual report

6 Nov 2023

Independent director Rajeshkumar Rasiklal resigns citing personal reasons; Dhrumil Gokani and another independent director appointed

Filing also notes a director who is son-in-law of the MD (promoter group)

13 Feb 2024

Statutory auditor (FRN 120457W, Rajkot) resigns, citing preoccupation; new auditor (FRN 125924W) appointed for FY2023-24

Second auditor exit in six months

8 Apr 2024

CS Dhaval Sureshkumar Raychura resigns

—

28–31 May 2024

Independent director Jaikishan Vasdev Wadhwani (DIN 10383327) resigns; new independent directors including Maulik M. Chavda appointed; committees reconstituted

—

10 Jul 2024

CFO Pradipkumar Harjibhai Lathiya resigns; Rajen P. Vyas appointed CFO

—

27 May 2025

Jay Pandya & Associates appointed secretarial auditor; internal auditor appointed for FY2025-26

—

7 Apr 2026

CS Vinita Sunil Thadani resigns, citing external career opportunities

—

27 Aug 2026

Board approves change of secretarial auditor

—

Governance Detail

CategoryMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Promoters (%)

62.9958.0736.0327.2027.2027.20

Public (%)

37.0141.9363.9872.8072.8172.81

Shareholders (count)

70522,77446,88940,11835,02231,376

Major Shareholders

HolderCategoryStake (%)Source

Dineshbhai Bhanushankar Pandya

Promoter

25.13 (MarketsMojo) / 25.4 (Simply Wall St)

Aggregators

Other promoter-group members

Promoter

About 2.07 (balance of the 27.20%)

Derived

JR Seamless Private Limited

Public (corporate)

2.46

MarketsMojo

Institutional investors (FII/DII/MF)

—

Nil / not disclosed (no institutional holders identified)

Screener pattern shows only promoter/public

Holders 4–10

Retail / individuals

Not publicly disclosed in sources accessed

—

Competitive Landscape

Key Competitors

CompetitorCategory overlapTypeApprox. scale (INR Cr; latest FY)Relative positioning vs. Add-Shop

Patanjali Ayurved / Patanjali Foods

Ayurveda, FMCG, food

Large private / listed

Patanjali Foods about 31,000–34,000 (FY2025, approx.)

Dominant mass-market Ayurveda brand with national retail distribution

Dabur India

Ayurveda OTC, personal care, food

Listed (NSE/BSE)

About 12,500 consolidated (FY2025, approx.)

Category leader; strong brands and distribution

Himalaya Wellness

Herbal personal care, OTC

Private

—

Strong pharmacy-led herbal brand

Baidyanath

Classical Ayurveda

Private

—

Traditional Ayurveda pharmacy brand

Amway India

Direct selling: nutrition, personal care, agri (limited)

Private (subsidiary of a US parent)

—

Largest direct-selling peer; premium nutrition

Vestige Marketing

Direct selling: wellness, agri ("Agri 82"), personal care

Private

—

Closest model peer (direct selling of wellness and agri products, rural reach)

Modicare

Direct selling: wellness, personal care

Private

—

Direct-selling peer

Godrej Agrovet

Animal feed, agri inputs

Listed

About 9,000–10,000 (FY2025, approx.)

Scale leader in compound feed

Coromandel International

Fertilisers incl. organic/bio-inputs

Listed

About 24,000 (FY2025, approx.)

Scale leader in agri inputs

Best Agrolife / regional bio-input makers

Agri inputs

Listed / private

—

Regional competition in bio-inputs

Dada Organics Ltd

Animal feed, Ayurveda, agri, cosmetics

Promoter-group entity

—

Both supplier and potential competitor; overlapping portfolio

“—” = not publicly disclosed.

Competitive Advantages & Vulnerabilities

AdvantagesVulnerabilities

Rural franchise network in Karnataka/AP/Telangana with farmer-level relationships (126 farmers recognised in a single 2022 programme)

Sub-scale: revenue under 1.5% of Dabur's

Bundled offering across agri, animal feed and wellness serves the same rural household

No brand pull outside its network; minimal advertising capacity

Promoter's social-entrepreneur narrative and decades of organic-farming advocacy

Dependence on related-party suppliers creates conflicts and margin opacity

Asset-light model (fixed assets of about INR 6 crore)

Working capital is the real asset base: 264 debtor days signals weak channel bargaining power

—

Direct-selling model is subject to the Consumer Protection (Direct Selling) Rules, 2021

Peer Comparison FY2026

MetricAdd-Shop E-Retail (FY2026)Dabur India (FY2025, approx.)Godrej Agrovet (FY2025, approx.)Patanjali Foods (FY2025, approx.)

Revenue (INR Cr)

154.6512,5009,40033,000

Revenue growth (%)

-0.3106

EBITDA margin (%)

2.11986

Net margin (%)

0.71444

R&D intensity (% revenue)

—

about 1 (approx.)

——

“—” = not publicly disclosed.

Recent Developments

The company's disclosure cadence has slowed sharply since 2023, with no business updates and only statutory filings. All identified events are listed below.

Company Snapshot

$17.9M

Revenue

$1.9M

Market Cap

2013

Founded

Rajkot, India

Headquarters

SWOT Analysis

Strengths

  • Revenue base retained at scale. Revenue held at about INR 155 crore in FY2025 and FY2026 and rebounded to INR 45.64 crore in Q1 FY2027 (+55% YoY), showing the distribution network still moves volume (Screener; Q1 FY2027 results).
  • Low leverage relative to equity. Debt/equity was 0.22x at FY2026, with borrowings cut from INR 38 crore to INR 25 crore in one year (Screener balance sheet).
  • Large equity cushion. Net worth is about INR 114 crore (book value INR 40.2/share), largely from the INR 48.9 crore 2022 rights issue and accumulated FY2021–FY2023 profits (Screener; rights issue filings).
  • Multi-state rural network. At least 160 franchises and 4 C&F agents were announced across Karnataka, AP, Telangana, TN, WB, Bihar, Maharashtra and UP in 2021–2023 alone, on top of 500+ outlets claimed in 2019 (BSE updates; IIFL).
  • Consistently profitable at the net level outside one quarter. Every quarter from Q1 FY2025 to Q1 FY2027 was profitable, albeit thinly (Screener quarterly data).
  • Diversified product basket. Products span Ayurveda, nutraceuticals, agri-inputs, animal feed, personal care, household, hygiene and Khadi, which reduces single-category dependence (Dec 2023 strategic update; MarketScreener).

Weaknesses

  • Collapsed profitability. OPM fell from 16% (FY2022) to 2.13% (FY2026); PAT fell from INR 19.09 crore to INR 1.05 crore (Screener; press release Apr 2022).
  • Severe working-capital stretch. Debtor days are 264 and the cash conversion cycle is 333 days (FY2026), so about INR 108 crore of capital is locked in working capital (Screener ratios).
  • Poor cash conversion. Cumulative CFO over FY2023–FY2025 was -INR 74 crore against reported cumulative PAT of about INR 25.7 crore (Screener cash flows).
  • Low promoter alignment. Promoter holding is 27.20%, down from 62.99% in FY2021, including a -8.83 percentage point decline over three years (Screener shareholding).
  • Governance instability. There were two statutory auditor resignations in six months (Aug 2023, Feb 2024), three CFOs since 2023 and three CS changes (BSE filings).
  • Minimal returns. ROE was 0.9% in FY2026 and averaged 2.3% over three years; ROCE was 2% (Screener).

Opportunities

  • Rural wellness and natural-farming tailwinds. Government promotion of natural/organic farming fits the company's farmer-facing agri-input line (sector context; company press releases).
  • Volume recovery. Q1 FY2027 revenue growth of 55% suggests the channel may be re-activating; operating leverage could lift margins from about 2% if sustained (Q1 FY2027 results).
  • Working-capital release. Collecting even half of the excess receivables (debtor days 264 vs. 53 in FY2022) could free INR 40–50 crore, more than twice the current market cap (Screener-derived).
  • Deep discount to book. P/B of about 0.14x means any credible governance or cash-flow improvement could re-rate the stock sharply (Screener).
  • Nutraceutical/urban extension. The Dec 2023 strategic update targets protein and nutraceutical products for urban lifestyles, a higher-margin category.
  • Debt paydown capacity. The FY2026 positive CFO of INR 8 crore plus an INR 18 crore investing inflow demonstrated the ability to deleverage when collections improve (Screener).

Threats

  • Related-party concentration. RPT frameworks of up to INR 250 crore per FY with Dada Organics, Dadaji Lifescience and Scarnose International exceed annual revenue, so margin and receivable quality may depend on intra-group terms (AGM notices 2023, 2026).
  • Receivable impairment risk. Receivables at 264 days risk write-offs. The Q4 FY2024 operating loss of INR 9.6 crore may have been an early instance (Screener quarterly data).
  • Direct-selling regulation. The Consumer Protection (Direct Selling) Rules, 2021 impose obligations on direct sellers and their networks. The company self-describes as a "direct selling company" (Dec 2023 update).
  • Retail-shareholder exodus and illiquidity. The shareholder count fell from 46,889 to 30,801 (Mar 2023 – Jun 2026). The stock trades below its bonus-adjusted IPO price (about INR 8.7) and about 89% below the INR 54 rights price (Screener; IPO/rights data).
  • Compliance continuity. The CS post fell vacant again in April 2026, raising risk of SEBI LODR non-compliance penalties (BSE filing 7 Apr 2026).
  • Competition from scaled brands. Dabur, Patanjali, Vestige, Amway and Godrej Agrovet have far larger brand and distribution budgets.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 May 2025FY2025 audited results: revenue INR 155.13 crore (-23.6%), PAT INR 3.32 crore (+5.1%); Q4 FY2025 PAT INR 0.36 crore vs. a INR 6.99 crore loss in Q4 FY2024Confirms revenue contraction; Q4 FY2025 OPM only 1.8%
27 May 2025Jay Pandya & Associates appointed secretarial auditor; internal auditor appointed for FY2025-26Compliance housekeeping
27 May 2025Half-yearly RPT disclosure filed (H2 FY2025)RPT scrutiny point
13 Aug 2025Q1 FY2026 results: revenue INR 29.41 crore (-27% YoY), PAT INR 0.21 crore (-82%); limited review by K M Chauhan and AssociatesTrough quarter
2 Sep 2025FY2024-25 annual report filedDescribes business as trading and distribution
Sep 2025Routine
11 Nov 2025Q2 FY2026 results: total income INR 33.40 crore (+7.05% YoY), PAT INR 0.23–0.29 crore (sources vary); total assets INR 129.57 crore vs. INR 155.46 crore at Mar 2025Balance-sheet shrinkage of about INR 26 crore in six months
Feb 2026Q3 FY2026 results: revenue INR 34.85 crore, PAT INR 0.26 croreGerman market commentary (boerse-global) flags a profit decline in the December quarter
Feb 2026Simply Wall St market cap about INR 23 crore at INR 8.14 (13 Feb 2026)Valuation reference
Apr 2026Market commentary rates the stock "very attractive" on P/E and P/B but flags weak fundamentals and falling returns on capitalValuation vs. quality debate
7 Apr 2026CS & Compliance Officer Vinita Sunil Thadani resignsThird CS change since 2023; compliance continuity risk
22 May 2026FY2026 audited results: revenue about INR 155 crore (flat), PAT INR 1.05 crore (-68%), OPM 2.13%Lowest profit since FY2020
11–15 Jun 2026Shares at INR 7.11–7.20; market cap about INR 20 crore; P/E about 19x; P/B 0.18—
12 Aug 2026Q1 FY2027 results: revenue INR 45.64 crore (+55% YoY), PAT INR 0.27 crore (+29%), OPM 1.88%Volume rebound, margins still minimal
Aug 2026MarketsMojo describes the June 2026 quarter trend as "flat" and downgrades the stock to "Strong Sell"Negative sentiment
19 Aug 2026Promoter-linked Scarnose International seeks shareholder approval for RPTs with Dada Organics, Dadaji Lifescience and Add-Shop E-RetailConfirms cross-company transaction web
24 Aug 2026Stock falls for a fifth straight session to an all-time low of INR 6.30Capitulation signal
27 Aug 2026Board approves material RPTs, a change of secretarial auditor and the 13th AGM date; FY2025-26 annual report filedRPT approvals of up to INR 250 crore sought
31 Aug 2026Book closure intimation (12–19 Sep 2026) and newspaper publicationRoutine
16 Sep 2026Share price INR 5.86; market cap INR 16.6 crore; 52-week range INR 5.26–10.00New lows below the Aug 2026 level
19 Sep 202613th AGM adopts FY2026 financials and approves RPTs with Dada Organics, Dadaji Lifescience and Scarnose InternationalShareholder sign-off on the RPT framework
25 Sep 2026Share price INR 5.70—
8 Oct 2026Share price INR 5.76 (+3.2% on the day); market cap about INR 16.3 croreLatest price reference

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (%): Contribution to total revenue held from 100% in FY2024 to 100% in FY2026.
Add-Shop E-Retail Limited — Revenue by Segment (%)
Series (%)FY2024FY2025FY2026
Contribution to total revenue100100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BSE filing: Strategic update, 19 Dec 2023 (bseindia.com)
  2. BSE filing: 25 new franchises, 12 Sep 2023 (bseindia.com)
  3. BSE filing: 4 C&F + 26 franchises, 1 Aug 2022 (bseindia.com)
  4. BSE filing: Award programmes, 21 Jun 2022 (bseindia.com)
  5. BSE filing: Rights issue oversubscription, 1 Sep 2022 (bseindia.com)
  6. BSE filing: Franchises & tulsi green tea, 6 Mar 2023 (bseindia.com)
  7. BSE filing: E-commerce & new products, 10 Jan 2022 (bseindia.com)
  8. BSE filing: Press release FY2022 results, 21 Apr 2022 (bseindia.com)
  9. BSE filing: Press release Q2 FY2023, 18 Oct 2022 (bseindia.com)
  10. BSE filing: Spices, tea & coffee launch, 25 Jul 2022 (bseindia.com)
  11. BSE filing: 35 franchises AP/Telangana, 27 May 2022 (bseindia.com)
  12. BSE filing: Business update, 27 Dec 2021 (bseindia.com)
  13. BSE filing: Franchise update, 6 Dec 2021 (bseindia.com)
  14. BSE filing: Board outcome 19 Aug 2023 (bseindia.com)
  15. BSE filing: 9th AGM annual report extract (bseindia.com)
  16. BSE filing: FY2023 annual report / 10th AGM notice (bseindia.com)
  17. BSE filing: 10th AGM outcome (bseindia.com)
  18. BSE filing: 9th AGM outcome (bseindia.com)
  19. BSE filing: Auditor resignation Feb 2024 (bseindia.com)
  20. BSE filing: Independent director changes Nov 2023 (bseindia.com)
  21. BSE filing: CS resignation Apr 2024 (bseindia.com)
  22. BSE filing: CFO change Jul 2024 (bseindia.com)
  23. BSE filing: Independent director resignation May 2024 (bseindia.com)
  24. BSE filing: Committee reconstitution May 2024 (bseindia.com)
  25. BSE filing: Board outcome 27 May 2025 (bsmedia.business-standard.com)
  26. BSE filing: Rights issue terms, 27 Jul 2022 (bseindia.com)
  27. BSE filing: Rights issue approval, 3 Jun 2022 (bseindia.com)
  28. BSE filing: Rights-issue fund utilisation statement, 25 Apr 2023 (bseindia.com)
  29. BSE filing: Bonus record date, 31 Dec 2021 (bseindia.com)
  30. BSE filing: RPT disclosure H2 FY2023 (bseindia.com)
  31. SEBI: Letter of Offer, Add-Shop E-Retail Limited (Aug 2022) (sebi.gov.in)
  32. Screener.in: Add-Shop E-Retail Ltd (financials, ratios, shareholding, documents) (screener.in)
  33. Business Standard / Capital Market: Q4 FY2025 and FY2025 results (27 May 2025) (business-standard.com)
  34. Business Standard / Capital Market: Q1 FY2025 results (12 Aug 2024) (business-standard.com)
  35. 5paisa: Q4 FY2024 results (5paisa.com)
  36. MarketsMojo: annual results, company CV, news (marketsmojo.com)
  37. Univest: Q1 FY2027 results (univest.in)
  38. Univest: Q4 FY2026 results (figures conflict with filings; flagged) (univest.in)
  39. ScanX: CS resignation Apr 2026; Q1/Q2 FY2026; 13th AGM (scanx.trade)
  40. ScanX: 13th AGM outcome (scanx.trade)
  41. ScanX: Scarnose International AGM / RPTs (scanx.trade)
  42. Simply Wall St: company information and management (simplywall.st)
  43. Upstox: share price and description (upstox.com)
  44. IIFL (indiainfoline): company summary, management, price (indiainfoline.com)
  45. Investing.com: company profile (m.uk.investing.com)
  46. Motilal Oswal: corporate actions (bonus history) (motilaloswal.com)
  47. Chittorgarh: SME IPO details (chittorgarh.com)
  48. IPO Central: listing performance (ipocentral.in)
  49. HDFC Securities: IPO objects and restated financials (hdfcsec.com)
  50. MarketScreener: Dev Dineshbhai Pandya insider profile (marketscreener.com)
  51. MarketScreener: Hemal Patel profile (Dada Organics founding detail) (de.marketscreener.com)
  52. BSE filing (Scarnose International): director appointments, 26 Mar 2024 (bseindia.com)
  53. IssueWire / DP Tribune: Gaupiyush capsule and Dadaji Home Mart (30 Jan 2022) (business.dptribune.com)
  54. Boerse-Global (German market commentary, 2026) (boerse-global.de)
  55. Value Research: FY2025 annual report and CS resignation announcements — valueresearchonline.com

Primary filings (BSE)

Financial data and news

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.